The abstract is read at the publisher; the summary is JClub's.
Rituximab treatment in Swedish adults with relapsing-remitting multiple sclerosis is linked to a higher new-onset inflammatory bowel disease risk, with 110 events per 100,000 person-years.
- Why it matters: Reports of IBD emerging during anti-CD20 therapy raised uncertainty about whether risk is truly higher than with other modern multiple sclerosis treatments and the general population.
- What they did: In a population-based Swedish cohort, therapy starts for rituximab, natalizumab, dimethyl fumarate, and fingolimod (2011–2023) were matched to general population comparator episodes, excluding prior IBD. New-onset IBD required at least 2 separate records using ICD-10 codes K50, K51, or K52.3.
- The result: After adjustment, comparator DMTs vs rituximab had a hazard ratio of 0.10 (95% CI, 0.04-0.22), and the number needed to harm for rituximab vs comparator DMTs was 131 at 5 years.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.